Clinical Study: Effectiveness of Triptorelin 0.1 mg in Improving Clinical Pregnancy Rates

Keywords: triptorelin 0.1 mg, clinical pregnancy rate, luteal phase support

Background of the Study

In assisted reproductive technology (ART), particularly in intracytoplasmic sperm injection (ICSI) cycles using GnRH antagonist protocols, maintaining an optimal hormonal environment during the luteal phase is crucial for successful embryo implantation and early pregnancy development.

The use of GnRH antagonists can lead to a suppression of pituitary gonadotropins — specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — which may negatively affect corpus luteum function and progesterone production. This can compromise endometrial receptivity and reduce clinical pregnancy rates.

To address this issue, researchers have explored the addition of triptorelin , a GnRH agonist, to standard progesterone-based luteal phase support (LPS) regimens.

A recent randomized controlled trial published in The Journal of Obstetrics and Gynecology of India in May 2025 investigated whether administering triptorelin 0.1 mg on day 6 after oocyte pickup (OPU) could enhance luteal function and improve reproductive outcomes in women undergoing ICSI with antagonist protocols.

Study Design and Methods

The study was an open-label, randomized controlled trial conducted at Women’s Health Hospital, Assiut University, involving 150 women who underwent antagonist-controlled ovarian hyperstimulation (COH) followed by ICSI.

Participants were randomly divided into two groups:

• Study Group (n = 75): Received 0.1 mg of triptorelin on day 6 after OPU in addition to vaginal progesterone starting from the day of OPU .
• Control Group (n = 75): Received vaginal progesterone only , starting from the day of OPU.

All participants were monitored for key reproductive outcomes including:

• Progesterone levels on day 7 after OPU
• Beta-human chorionic gonadotropin (β-hCG) levels on day 14 post-embryo transfer
• Fetal pulsation
• Implantation rate
• Clinical pregnancy rate
• Biochemical pregnancy rate
• Ongoing pregnancy and live birth rates

Key Results and Findings

The group receiving triptorelin + progesterone demonstrated significantly better outcomes across multiple parameters compared to the progesterone-only group:

These results indicate that adding triptorelin 0.1 mg during the luteal phase significantly enhances hormonal support and improves reproductive outcomes in antagonist ICSI cycles.

Why These Findings Matter

The administration of triptorelin six days after oocyte pickup appears to stimulate the pituitary gland to release LH and FSH, which in turn boosts steroidogenesis (production of estradiol and progesterone) by the corpus luteum.

This mechanism helps maintain adequate progesterone levels, which are essential for:

• Endometrial preparation
• Embryo implantation
• Early pregnancy maintenance

The observed improvements in clinical and ongoing pregnancy rates suggest that triptorelin supplementation can be a valuable addition to standard LPS protocols , especially in antagonist cycles where natural luteal function may be compromised.

Conclusion

The clinical study provides strong evidence that adding triptorelin 0.1 mg to progesterone-based LPS significantly improves reproductive outcomes in women undergoing ICSI with antagonist protocols.

By restoring pituitary function and enhancing luteal steroid production, triptorelin contributes to better endometrial receptivity and higher chances of successful implantation and clinical pregnancy.

As more research continues to explore the optimal timing and dosage of triptorelin, its role in modern ART protocols is becoming increasingly well-supported by scientific data.

🔍 References

1. Zahran, K. M., Ahmed, M. M. A., Farghaly, T. A., Elsayed, A. A., & El-Nashar, I. M. (2025). Triptorelin 0.1 mg as a Luteal Phase Support in Antagonist Intracytoplasmic Sperm Injection Cycles . The Journal of Obstetrics and Gynecology of India.
   https://doi.org/10.1007/s13224-025-01895-z

2. Al-Inany, H. G., Abou-Setta, A. M., & Mansour, R. T. (2006). Adding gonadotropin-releasing hormone agonist to progesterone for luteal phase support in intra-cytoplasmic sperm injection cycles: a prospective, randomized, controlled trial . Fertility and Sterility, 85(2), 441–445.
   https://doi.org/10.1016/j.fertnstert.2005.07.1345

3. Orvieto, R. (2017). Is there a place for GnRH-agonist in the luteal phase support of ART cycles? Gynecological Endocrinology, 33(6), 427–430.
   https://doi.org/10.1080/09513590.2017.1296817

4. Youssef, M. A. F. M., van der Veen, F., Al-Inany, H. G., et al. (2019). Gonadotrophin-releasing hormone agonist versus HCG for oocyte triggering in GnRH antagonist IVF cycles . Cochrane Database of Systematic Reviews, Issue 3.
   https://doi.org/10.1002/14651858.CD008046.pub3